Schrödinger Inc. announced Ramy Farid's serves as a director at three public companies Schrdinger Inc., Vir Biotechnology Inc. and Structure Therapeutics Inc. (Structure). Dr. Farid's term on the board of directors of Structure will expire on June 25, 2024 at Structure's 2024 annual general meeting of shareholders, and Dr. Farid is not standing for re-election to Structure's board of directors. Once Dr. Farid's term on the board of directors of Structure ends on June 25, 2024, Dr. Farid will be serving on only two public company boards, one of which will be the Company's board of directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.57 USD | -2.52% |
|
-5.40% | +11.80% |
06-07 | Structure Therapeutics Closes $547.4 Million Offering | MT |
06-07 | BMO Capital Adjusts Price Target on Structure Therapeutics to $100 From $83, Maintains Outperform Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.80% | 2.12B | |
+15.19% | 121B | |
+19.91% | 114B | |
+19.13% | 23.61B | |
-19.80% | 20.43B | |
-15.64% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B |
- Stock Market
- Equities
- GPCR Stock
- News Structure Therapeutics Inc.
- Structure Therapeutics Inc. Announces Ramy Farid Not Standing for Re-Election to Board of Directors, Term Expire on June 25, 2024